English Swedish
Published: 2022-05-11 07:30:00 CEST
Surgical Science Sweden AB
Interim information

Interim report January-March 2022: A STRONG START TO THE YEAR

FIRST QUARTER 2022 (JAN – MAR)

Net sales amounted to SEK 159.1 million (37.2), corresponding to an increase of 328 percent compared with the corresponding period in the preceding year.

Simbionix is included in the amount of SEK 115.2 million. For comparable units, sales increased by 32 percent.

Operating profit amounted to SEK 20.0 million (2.2).

Net profit amounted to SEK 16.5 million (1.5), corresponding to earnings per share of SEK 0.32 (0.04).

Cash flow from operating activities amounted to an inflow of SEK 11.1 million (outflow 8.9). As of March 31, 2022, cash and cash equivalents amounted to SEK 329.9 million (263.7).

Gothenburg, Sweden, May 11, 2022
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.


220511 Q12022 ENG.pdf